Rhumbline Advisers Nuvectis Pharma, Inc. Transaction History
Rhumbline Advisers
- $113 Billion
- Q2 2025
A detailed history of Rhumbline Advisers transactions in Nuvectis Pharma, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 12,678 shares of NVCT stock, worth $77,462. This represents 0.0% of its overall portfolio holdings.
Number of Shares
12,678Holding current value
$77,462% of portfolio
0.0%Shares
5 transactions
Others Institutions Holding NVCT
# of Institutions
50Shares Held
3.21MCall Options Held
44.5KPut Options Held
50.1K-
Vanguard Group Inc Valley Forge, PA667KShares$4.07 Million0.0% of portfolio
-
Ronit Capital LLP563KShares$3.44 Million5.37% of portfolio
-
Iridian Asset Management LLC373KShares$2.28 Million1.01% of portfolio
-
Baldwin Brothers LLC350KShares$2.14 Million0.19% of portfolio
-
Geode Capital Management, LLC Boston, MA285KShares$1.74 Million0.0% of portfolio
About Nuvectis Pharma, Inc.
- Ticker NVCT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 14,642,500
- Market Cap $89.5M
- Description
- Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src...